Which two antipsychotics have the highest overall liability for metabolic abnormalities?

• A. Clozapine and Olanzapine
• B. Quetiapine and Risperidone
• C. Ziprasidone and Aripiprazole
• D. Lurasidone and Paliperidone

Answer: (A)

Metabolic consequences are a major consideration with antipsychotics. Some drugs carry a higher risk of weight gain, dyslipidemia, and glucose intolerance than others. Among the options, two agents stand out for having the strongest association with metabolic abnormalities: olanzapine and clozapine. Olanzapine tends to produce the most weight gain and lipid changes, and both drugs are linked to higher rates of impaired glucose tolerance and diabetes. This likely relates to potent antagonism of histamine H1 and serotonin 2C receptors, which drives increased appetite and adverse metabolic effects.

Other antipsychotics listed have comparatively lower metabolic risk. Ziprasidone and ariprazole are often described as weight-neutral or metabolic-friendly. Quetiapine and risperidone do carry metabolic risks but not to the same extent as olanzapine and clozapine. Lurasidone and paliperidone generally show more favorable metabolic profiles as well.

In practice, this means when a patient has obesity, diabetes, or metabolic syndrome risk, clinicians may prefer agents with lower metabolic impact and implement closer metabolic monitoring (weight, waist circumference, fasting glucose/HbA1c, lipid panel) after starting or changing therapy.